Clinical Trial Update: Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the impact of empagliflozin on exercise capacity and left ventricular diastolic function in patients with heart failure with preserved e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | Conditions: Heart Failure, Diastolic, Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED